Back to Research Center

Bright Minds Bio

An interview with Gideon Shapiro, Co-Founder & VP of Discovery at Bright Minds Biosciences, where we discuss recent and upcoming events in psychedelic drug development.  We cover Bright Minds pipeline of 5HT2 agonists, the importance of FDA’s approval of Spravato, and Compass’s impending Ph2b psilocybin data, among other topics relevant in the psychedelic space.

To listen on Podbean click here

Apple Podcasts here

Spotify click here

YouTube click here